Press release
Geron Announces ASCO Presentation Reporting Durable Continuous Transfusion Independence with Imetelstat in IMerge Phase 3 Lower Risk MDS Patients
Primary endpoint of 8-week transfusion independence (TI) significantly higher with imetelstat vs. placebo
About this update from Geron Corporation
[{"type":"text","content":"\n\nPrimary endpoint of 8-week transfusion independence (TI) significantly higher with imetelstat vs. placebo (P","length":151,"tagName":"div"}]